Ironwood spinout sees path forward for platform despite lead program miss

Two failed Phase II trials of its most advanced candidate sent Cyclerion tumbling just months after the company’s split from Ironwood. Despite the miss for praliciguat, the company sees signs of optimism for the platform.

Cyclerion Therapeutics Inc. (NASDAQ:CYCN) shares fell $10.68 (80%) to $2.75 after the company announced its lead soluble guanylate cyclase (sGC) candidate failed in two different indications. The $293 million loss in valuation took the company’s market cap to about $75 million, below its current

Read the full 786 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE